Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
541
-
Total 13F shares, excl. options
-
116M
-
Shares change
-
-3.52M
-
Total reported value, excl. options
-
$6.05B
-
Value change
-
-$203M
-
Put/Call ratio
-
0.95
-
Number of buys
-
260
-
Number of sells
-
-295
-
Price
-
$52.02
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2025
637 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q2 2025.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 541 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 116M shares
of 124M outstanding shares and own 94.03% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (13.2M shares), VANGUARD GROUP INC (12.2M shares), STATE STREET CORP (5.94M shares), Invesco Ltd. (3.47M shares), SNYDER CAPITAL MANAGEMENT L P (3.4M shares), ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (2.54M shares), ALLIANCEBERNSTEIN L.P. (2.46M shares), GEODE CAPITAL MANAGEMENT, LLC (2.43M shares), MACQUARIE GROUP LTD (2.08M shares), and BANK OF AMERICA CORP /DE/ (2.07M shares).
This table shows the top 541 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.